Abstract
Chromosomal breakpoints involving the MYC gene locus, frequently referred to as MYC rearrangements (MYC − R+), are a diagnostic hallmark of Burkitt lymphoma and recurrent in many other subtypes of B-cell lymphomas including follicular lymphoma, diffuse large B-cell lymphoma and other high-grade B-cell lymphomas and are associated with an aggressive clinical course. In remarkable contrast, in MCL, only few MYC − R+ cases have yet been described. In the current study, we have retrospectively analysed 16 samples (MYC − R+, n = 15, MYC − R−, n = 1) from 13 patients and describe their morphological, immunophenotypic and (molecular) genetic features and clonal evolution patterns. Thirteen out of fifteen MYC − R+ samples showed a non-classical cytology including pleomorphic (centroblastic, immunoblastic), anaplastic or blastoid. MYC translocation partners were IG-loci in 4/11 and non-IG loci in 7/11 analysed cases. The involved IG-loci included IGH in 3 cases and IGL in one case. PAX5 was the non-IG partner in 2/7 patients. The MYC − R+ MCL reported herein frequently displayed characteristics associated with an aggressive clinical course including high genomic-complexity (6/7 samples), frequent deletions involving the CDKN2A locus (7/10 samples), high Ki-67 proliferation index (12/13 samples) and frequent P53 expression (13/13 samples). Of note, in 4/14 samples, SOX11 was not or only focally expressed and 3/13 samples showed focal or diffuse TdT-positivity presenting a diagnostic challenge as these features could point to a differential diagnosis of diffuse large B-cell lymphoma and/or lymphoblastic lymphoma/leukaemia.
Similar content being viewed by others
References
Dreyling M, Klapper W, Rule S (2018) Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood 132:2722–2729. https://doi.org/10.1182/blood-2017-08-737502
Sander B, Quintanilla-Martinez L, Ott G, Xerri L, Kuzu I, Chan JKC, Swerdlow SH, Campo E (2016) Mantle cell lymphoma--a spectrum from indolent to aggressive disease. Virchows Arch 468:245–257. https://doi.org/10.1007/s00428-015-1840-6
López C, Kleinheinz K, Aukema SM et al (2019) Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun 10:1459. https://doi.org/10.1038/s41467-019-08578-3
Christie L, Kernohan N, Levison D, Sales M, Cunningham J, Gillespie K, Batstone P, Meiklejohn D, Goodlad J (2008) C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: an adverse prognostic indicator? Leuk Lymphoma 49:470–476. https://doi.org/10.1080/10428190701836845
Ziemba JB, Wolf Z, Weinstock M, Asakrah S (2020) Double-hit and triple-hit follicular lymphoma. Am J Clin Pathol 153:672–685. https://doi.org/10.1093/ajcp/aqz208
Aukema SM, van Pel R, Nagel I, Bens S, Siebert R, Rosati S, van den Berg E, Bosga-Bouwer AG, Kibbelaar RE, Hoogendoorn M, van Imhoff GW, Kluin-Nelemans HC, Kluin PM, Nijland M (2017) MYC expression and translocation analyses in low-grade and transformed follicular lymphoma. Histopathology 71:960–971. https://doi.org/10.1111/his.13316
Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM (2011) Double-hit B-cell lymphomas. Blood 117:2319–2331. https://doi.org/10.1182/blood-2010-09-297879
Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G (2017) B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. Blood 129:333–346. https://doi.org/10.1182/blood-2016-05-718775
Hu Z, Medeiros LJ, Chen Z, Chen W, Li S, Konoplev SN, Lu X, Pham LV, Young KH, Wang W, Hu S (2017) Mantle cell lymphoma with MYC rearrangement: a report of 17 patients. Am J Surg Pathol 41:216–224. https://doi.org/10.1097/PAS.0000000000000758
Wang L, Tang G, Medeiros LJ, Xu J, Huang W, Yin CC, Wang M, Jain P, Lin P, Li S (2020) MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica.:haematol.2019.243071. https://doi.org/10.3324/haematol.2019.243071
Kallen ME, Rao NP, Kulkarni SK, Pullarkat ST, Said J, Tirado CA, Ahmed RS, Miller JM, Chung PY, Kahn DG, Song SX (2015) B-lymphoblastic transformation of mantle cell lymphoma/leukemia with “double hit” changes. J Hematop 8:31–36. https://doi.org/10.1007/s12308-014-0229-9
Wagener R, López C, Kleinheinz K, Bausinger J, Aukema SM, Nagel I, Toprak UH, Seufert J, Altmüller J, Thiele H, Schneider C, Kolarova J, Park J, Hübschmann D, Murga Penas EM, Drexler HG, Attarbaschi A, Hovland R, Kjeldsen E, Kneba M, Kontny U, de Leval L, Nürnberg P, Oschlies I, Oscier D, Schlegelberger B, Stilgenbauer S, Wössmann W, Schlesner M, Burkhardt B, Klapper W, Jaffe ES, Küppers R, Siebert R (2018) IG-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. Blood 132:2280–2285. https://doi.org/10.1182/blood-2018-03-842088
Patel KP, Khokhar FA, Muzzafar T, James You M, Bueso-Ramos CE, Ravandi F, Pierce S, Medeiros LJ (2013) TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. Mod Pathol 26:195–203. https://doi.org/10.1038/modpathol.2012.142
Ok CY, Medeiros LJ, Thakral B, Tang G, Jain N, Jabbour E, Pierce SA, Konoplev S (2019) High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma. Mod Pathol 32:48–58. https://doi.org/10.1038/s41379-018-0112-9
Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TFE, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kühn M, Lenze D, Lichter P, Martin-Subero JI, Möller P, Müller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Trümper L, Stein H, Siebert R (2006) A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419–2430. https://doi.org/10.1056/NEJMoa055351
Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Kuppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M, Schwaenen C, Stein H, Trautmann H, Wessendorf S, Trumper L, Loeffler M, Spang R, Kluin PM, Klapper W, Siebert R, for the Molecular Mechanisms in Malignant Lymphomas (MMML) Network Project (2014) Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica 99:726–735. https://doi.org/10.3324/haematol.2013.091827
Klapper W, Hoster E, Determann O et al (2009) Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2:103–111. https://doi.org/10.1007/s12308-009-0036-x
Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, Thorns C, Hartmann S, Kluin-Nelemans H, Hermine O, Dreyling M, Klapper W (2018) Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood 131:417–420. https://doi.org/10.1182/blood-2017-07-797019
Croci GA, Hoster E, Bea S et al (2020) Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. Virchows Arch 477:259–267. https://doi.org/10.1007/s00428-020-02750-7
McGowan-Jordan J, Simons A, Schmid M (Eds) (2016) ISCN 2016 An international system for human cytogenomic nomenclature. Karger, Basel.
Aukema SM, Theil L, Rohde M, Bauer B, Bradtke J, Burkhardt B, Bonn BR, Claviez A, Gattenlöhner S, Makarova O, Nagel I, Oschlies I, Pott C, Szczepanowski M, Traulsen A, Kluin PM, Klapper W, Siebert R, Murga Penas EM (2015) Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. Br J Haematol 170:814–825. https://doi.org/10.1111/bjh.13501
Martin-Subero JI, Harder L, Gesk S et al (2002) Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 98:470–474. https://doi.org/10.1002/ijc.10169
Kluin P, Schuuring E (2011) Molecular cytogenetics of lymphoma: where do we stand in 2010? Histopathology 58(1):128–144. https://doi.org/10.1111/j.1365-2559.2010.03700.x
Craig FE, Foon KA (2008) Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111(8):3941–3967. https://doi.org/10.1182/blood-2007-11-120535
Pizzi M, Agostinelli C, Righi S, Gazzola A, Mannu C, Galuppini F, Fassan M, Visentin A, Piazza F, Semenzato GC, Rugge M, Sabattini E (2017) Aberrant expression of CD10 and BCL6 in mantle cell lymphoma. Histopathology 71:769–777. https://doi.org/10.1111/his.13286
Xu J, Medeiros LJ, Saksena A et al (2018) CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases. Oncotarget 9:11441–11450. https://doi.org/10.18632/oncotarget.23571
Chuang W-Y, Chang H, Chang G-J, Wang TH, Chang YS, Wang TH, Yeh CJ, Ueng SH, Chien HP, Chang CY, Wan YL, Hsueh C (2017) Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. Histopathology 70:986–999. https://doi.org/10.1111/his.13161
Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B (2012) Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 119:4215–4223. https://doi.org/10.1182/blood-2011-12-400580
Cantu D, Alvarado Y, Murata-Collins J, Weisenburger DD (2019) Blastic transformation of mantle cell lymphoma with B-lymphoblastic features. Hum Pathol 17:200313. https://doi.org/10.1016/J.EHPC.2019.200313
Pizzi M, Brignola S, Righi S, Agostinelli C, Bertuzzi C, Pillon M, Semenzato G, Rugge M, Sabattini E (2018) Benign TdT-positive cells in pediatric and adult lymph nodes: a potential diagnostic pitfall. Hum Pathol 81:131–137. https://doi.org/10.1016/j.humpath.2018.06.027
Slot LM, Hoogeboom R, Smit LA, Wormhoudt TAM, Biemond BJ, Oud MECM, Schilder-Tol EJM, Mulder AB, Jongejan A, van Kampen AHC, Kluin PM, Guikema JEJ, Bende RJ, van Noesel CJM (2016) B-lymphoblastic lymphomas evolving from follicular lymphomas co-express surrogate light chains and mutated gamma heavy chains. Am J Pathol 186:3273–3284. https://doi.org/10.1016/j.ajpath.2016.07.027
Zhou D-M, Chen G, Zheng X-W, Zhu WF, Chen BZ (2015) Clinicopathologic features of 112 cases with mantle cell lymphoma. Cancer Biol Med 12:46–52. https://doi.org/10.7497/j.issn.2095-3941.2015.0007
de Jong D, Voetdijk BM, Beverstock GC et al (1988) Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med 318:1373–1378. https://doi.org/10.1056/NEJM198805263182106
Nadeu F, Martin-Garcia D, Clot G, Díaz-Navarro A, Duran-Ferrer M, Navarro A, Vilarrasa-Blasi R, Kulis M, Royo R, Gutiérrez-Abril J, Valdés-Mas R, López C, Chapaprieta V, Puiggros M, Castellano G, Costa D, Aymerich M, Jares P, Espinet B, Muntañola A, Ribera-Cortada I, Siebert R, Colomer D, Torrents D, Gine E, López-Guillermo A, Küppers R, Martin-Subero JI, Puente XS, Beà S, Campo E (2020) Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes. Blood. 136:1419–1432. https://doi.org/10.1182/blood.2020005289
Jares P, Colomer D, Campo E (2012) Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 122:3416–3423. https://doi.org/10.1172/JCI61272
Malarikova D, Berkova A, Obr A et al (2020) Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. Cancers 12. https://doi.org/10.3390/cancers12082120
Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann C, Räty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Grønbæk K (2017) TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 130:1903–1910. https://doi.org/10.1182/blood-2017-04-779736
Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Beà S (2011) The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol 21:322–334. https://doi.org/10.1016/j.semcancer.2011.09.007
Delfau-Larue M-H, Klapper W, Berger F, Jardin F, Briere J, Salles G, Casasnovas O, Feugier P, Haioun C, Ribrag V, Thieblemont C, Unterhalt M, Dreyling M, Macintyre E, Pott C, Hermine O, Hoster E, European Mantle Cell Lymphoma Network (2015) High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood 126:604–611. https://doi.org/10.1182/blood-2015-02-628792
Streich L, Sukhanova M, Lu X, Chen YH, Venkataraman G, Mathews S, Zhang S, Kelemen K, Segal J, Gao J, Gordon L, Chen Q, Behdad A (2020) Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss and TP53 mutations: a multi-institutional study. Genes Chromosom Cancer 59:484–494. https://doi.org/10.1002/gcc.22849
Rodrigues JM, Hassan M, Freiburghaus C, Eskelund CW, Geisler C, Räty R, Kolstad A, Sundström C, Glimelius I, Grønbæk K, Kwiecinska A, Porwit A, Jerkeman M, Ek S (2020) p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. Br J Haematol 191:796–805. https://doi.org/10.1111/bjh.17023
Friedberg JW (2017) How I treat double-hit lymphoma. Blood 130:590–596. https://doi.org/10.1182/blood-2017-04-737320
Funding
The research of W.K. and R.S. on MYC positive lymphomas is supported in the framework of a MMML-MYC-SYS grant (036166B) by the German Ministry of Science and Education (BMBF). Former grant support of MMML by the Deutsche Krebshilfe (2003–2011) and the support of the technical staff of the Institutes of Human Genetics in Kiel and Ulm are gratefully acknowledged. Work in Leicester supported by Cancer Research UK in conjunction with the UK Department of Health on an Experimental Cancer Medicine Centre grant [C10604/A25151].
Author information
Authors and Affiliations
Contributions
S.M.A., G.A.C., R.S. and W.K. designed the research; G.O., A.R., E.v/d B., A.B-B., M.H., I.B., E.H., M.K., W.B. S.J. and M.J.S.D. provided clinical, genetic and/or pathological data and samples; S.M.A, R.W., S.B., K.O-H., M.K., J.B., I.N., E.M.P. and R.S. performed (molecular)cytogenetic, molecular and/or bio-informatical analyses; G.A.C., P.K., I.O. and W.K. performed histopathological review; S.M.A., G.A.C., R.S. and W.K. wrote the manuscript; all authors approved the final version of the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethics approval
The study was conducted in accordance with the recommendations of the ethics board of the Medical Faculty, University of Kiel, numbers D425/03, D447/10 and amendment from 09.03.2010 which includes that based on the historic nature of several cases a written informed consent on participation and publication could not be obtained.
Consent to participate
See the ‘Ethics approval’ section.
Consent for publication
See the ‘Ethics approval’ section.
Code availability
NA
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
ESM 1
(PDF 667 kb).
Rights and permissions
About this article
Cite this article
Aukema, S.M., Croci, G.A., Bens, S. et al. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. Virchows Arch 479, 133–145 (2021). https://doi.org/10.1007/s00428-021-03022-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-021-03022-8